keep Transitional provisions relating to the Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025
Amendment to the Medicines for Human Use (Clinical Trials) Regulations 2004, updating the UK clinical trials framework post-Brexit. Key changes include: replacing 'subject' with 'participant' terminology; updating from EU Directive 2001/20/EC to EU Regulation 536/2014; introducing 'notifiable trial' concept for lower-risk trials; streamlining ethics committee establishment and operation; clarifying definitions for 'chief investigator', 'investigator', and 'trial location'; and replacing 'authorisation' with 'approval' terminology throughout. Extends to all UK jurisdictions.
This amendment represents a pragmatic post-Brexit update that retains essential safety protections while introducing proportionate requirements for lower-risk 'notifiable trials' and clarifying ambiguous definitions. The 2004 regulations as originally drafted contained EU-derived bureaucratic complexity; this amendment at least partially addresses that by creating a tiered approach. Deleting it would leave the 2004 regulations in force with outdated EU references and inconsistent terminology, creating greater confusion and potential compliance burdens. The core requirements—ethics committee review, licensing authority approval, sponsor responsibilities—remain necessary safeguards against harmful experimentation that the free market cannot self-regulate.